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Methylprednisolone dosage effects on peripheral lymphocyte subpop-
ulations and eicosanojd synthesis. Glucocorticoids have a major role in
the treatment of glomerular diseases. Despite recent advances in
understanding of their mechanism of action, very few studies have
addressed the relative advantage of the wide range of different dose
regimens employed in clinical practice. We studied the effects of
methyiprednisolone given intravenously for three consecutive days at
the doses of 1 mg/kg (group I, N = 7; group 2, N = 5), 5 mglkg (group
3, N = 5) or 15 mglkg (group 4, N = 6) on total blood peripheral
leukocytes and on lymphocyte subsets in patients with glomerular
diseases, and investigated whether such effects were a function of the
drug concentration in the blood. Since glucocorticoids have an inhibi-
tory effect on the formation of eicosanoids in different cells, we also
investigated in the same patients the effect of 1 and 15 mg/kg methyl-
prednisolone on systemic and renal eicosanoid synthesis. Results of
pharmacokinetic study showed that the three different doses of meth-
ylprednisolone we used resulted in major differences in patient's
exposure to the drug, and within the same dose there was a great
individual variability. By contrast the three different doses of methyl-
prednisolone induced a comparable drop in the absolute number of
lymphocytes six hours after the first injection of methylprednisolone,
while 24 hours later blood lymphocyte counts returned to the pre-
injection values in all patients. Analysis of lymphocyte subsets showed
a selective decrease in the number of circulating CD4 and CD8 cells
six hours after methylprednisolone which was comparable in the four
groups of patients studied. As for the effect of methyiprednisolone on
systemic and renal eicosanoid synthesis in patients with glomerular
diseases, 1 and 15 mg/kg were equally unable to reduce thromboxane A2
(TxA2) and prostaglandin E2 (PGE2) release by circulating polimorpho-
nuclear cells (PMN5). By contrast, methylprednisolone partially inhib-
ited eicosanoid synthesis by PMNs in vitro. Consistent with the data on
PMNs, urinary excretion of TxA2 and prostacyclin (PGL2) metabolites
were unaltered by the different doses of methylprednisolone. By
contrast urinary POE2 was markedly and significantly reduced in
patients given 15 but not 1 mg/kg. We conclude that 1 mg/kg methyl-
prednisolone given to patients with glomerular diseases has the same
effect on peripheral total blood leukocyte count and lymphocyte subsets
than 5 and 15 mg/kg. The same is true for eicosanoid synthesis by
PMNs. Renal synthesis of PGE2 is inhibited by 15 mg/kg but not by 1
mg/kg. This effect of the highest dose of methylprednisolone might not
be desirable, since it has been demonstrated that in patients with renal
disease renal function is dependent on intact renal POE2 synthesis.
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Glucocorticoids are widely used for the treatment of glomer-
ular disease [1] but the risk/benefit profile is still matter of
debate [21. Which dose and how long are questions still waiting
for an educated answer in this field. While some trials offered
positive results [3, 4], others ended with puzzling or negative
findings [5, 6]. As a result range of doses from 0.5 mg/kg (of
prednisone) to some 30 mg/kg (of methylprednisolone) is still in
use in various protocols with almost no rationale for such
discrepancies [7, 8]. The issue is an important one if one
considers that very high doses of steroids are associated with
serious side effects [9] and with the risk of hemodynamically
mediated injury as indicated by recent animal studies [10]. On
the other hand new biology techniques have expanded in a
substantial way the knowledges on glucocorticoids mecha-
nism(s) of action [11].
Some studies have been done in normal subjects [12, 13] on
the effect of different doses of steroids on laboratory and
biochemical parameters, but very few data are available in
patients [14, 15] particularly for the doses that are commonly
employed in clinical practice.
Here we sought to evaluate the effect of three different doses
of methylprednisolone on total blood peripheral leukocytes and
on lymphocyte subsets in patients with glomerular diseases and
to clarify whether such effects were a function of the drug
concentration in the blood. We also investigated in the same
patients the effect of methylprednisolone on systemic and renal
eicosanoid synthesis.
Methods
Subjects
Twenty-three patients (8 males and 15 females, 14 to 71 years
of age) who had been referred to the Division of Nephrology
and Dialysis of the Ospedali Riuniti di Bergamo between March
1989 and January 1992 were enrolled in the study. Informed
consent was obtained from each patient. Enrollment criteria
were the presence of a biopsy proven glomerulopathy that
would have required, by commonly used protocols, treatment
with glucocorticoids alone or in combination with immunosup-
pressive agents. Exclusion criteria were previous exposure to
glucocorticoids or cytotoxic drugs, concomitant hematological
diseases, neoplasia, moderate hypertension, the use of drugs
981
982 Rota et a!: Glucocorticoids and glomerular diseases
Table 1. Clinical, laboratory and histological findings of patients
Serum Creatinine
Age creatinine clearance Proteinuria
Sex years Histological finding pjnol/!iter mI/mm 9/24 hr
Group I
1 M 19 Minimal change glomerulopathy 97 151 8.8
2 F 19 Minimal change glomerulopathy 97 65 6.4
3 F 35 Minimal change glomerulopathy 80 138 4.2
4 F 28 Minimal change glomerulopathy 80 67 9.2
5 F 56 Focal glomerulosclerosis 71 45 1.6
6 F 54 Focal glomerulosclerosis 62 128 7.6
7 M 55 Focal glomerulosclerosis 751 3 4
Mean SD 177 253 85 54 5.9 2.8
Group 2
8 F 69 Idiopathic diffuse proliferative glomerulonephritis 407 14 2.97
9 F 43 Idiopathic diffuse proliferative glomerulonephntis 539 10 0.6
10 F 64 Idiopathic diffuse proliferative glomerulonephritis 265 24 2.6
11 M 59 Idiopathic diffuse proliferative glomerulonephritis 301 40 2.6
12 F 60 Diffuse proliferative cryoglobulinemic glomerulonephritis 239 21 6.2
Mean SD 350 123 22 12 3.0 2.0
Group 3
13 M 15 Minimal change glomerulopathy 230 4 10
14 F 14 Focal proliferative glomerulonephritis 159 45 0.5
15 F 60 Focal proliferative glomerulonephritis 318 31 3
16 M 71 Idiopathic diffuse proliferative glomerulonephritis 972 4 4
17 F 60 Diffuse proliferative cryoglobulinemic glomerulonephritis 71 65 7
Mean SD 350 359 30 26 4.9 3.7
Group 4
18 M 26 Idiopathic diffuse proliferative glomerulonephritis 380 20 4
19 M 56 Idiopathic diffuse proliferative glomerulonephritis 247 42 3.7
20 F 53 Idiopathic diffuse proliferative glomerulonephritis 282 32 0.3
21 F 46 Diffuse proliferative lupus nephritis 97 87 6
22 F 18 Diffuse proliferative lupus nephritis 265 8 6
23 M 62 Diffuse proliferative cryoglobulinemic glomerulonephritis 698 7 10
Mean SD 328 202 33 29 5.1 3.2
that may alter the pharmacokinetic properties of glucocorti-
coids or drugs affecting the formation of renal or systemic
eicosanoids, need for blood transfusion and uremia requiring
dialysis. Histological evaluation was assessed by means of light
microscopy, immunofluorescence and electron microscopy.
Five patients had minimal change glomerulopathy, three pa-
tients had focal and segmental glomerulosclerosis, two patients
had focal proliferative glomerulonephritis, 13 patients had dif-
fuse proliferative glomerulonephritis.
Study design
Subjects taking part to the study were divided into four
groups which were given 1 mg/kg/day (group 1, N = 7 and group
2, N = 5), 5 mg/kg/day (group 3, N = 5) or 15 mg/kg/day (group
4, N = 6) methylprednisolone by a 25-minute intravenous
infusion. Group 1 included four patients with minimal change
glomerulopathy and three patients with focal segmental glomer-
uloscierosis; groups 2 and 4 consisted of patients with diffuse
proliferative glomerulonephritis; group 3 included two patients
with focal, two patients with diffuse proliferative glomerulone-
phritis and one patient with minimal change glomerulopathy.
Clinical, laboratory and histological findings are reported in
Table 1.
To confirm the compliance with the protocol and measure
methylprednisolone pharmacokinetics, steroid plasmatic levels
were measured in all patients before the starting of the infusion,
immediately at the end of the infusion (t 0), and 15, 30, 45
minutes, 1, 2, 4, 6, 8, 10, 12, 24 hours after the end of the first,
and 24 hours after the third methylprednisolone infusion. Meth-
ylprednisolone plasma protein binding was also evaluated to
exclude that a non-linear binding may influence steroid phar-
macokinetics. Plasma protein binding was measured at 30
minutes, 6 and 12 hours after the first steroid infusion.
To evaluate the effect of the various doses of methylprednis-
olone on cellular and antibody immune system, leukocyte
count, lymphocyte subset kinetics (CD4: T helper/inducer,
CD8: T cytotoxic/suppressor, CDl6: NK cells, CDl9: B
lymphocytes) and serum concentrations of IgG, IgA and 1gM
were evaluated before, 6 and 24 hours after the first infusion and
24 hours after the third infusion of methylprednisolone.
To assess whether steroids may exert their anti-inflammatory
effect also suppressing the formation of eicosanoids, thrombox-
ane B2 (TxB2) and prostaglandin E2 (PGE2) production by
polymorphonuclear cells (PMNs) ex vivo was evaluated in
patients receiving 1 and 15 mg/kg methylprednisolone at the
same intervals considered for the assessment of lymphocyte
subsets. Timing collections were chosen on the basis of the
reported data showing a maximum drop of lymphocytes count
at four to six hours after glucocorticoid administration and
complete recovery within 24 hours [16]. A further collection
was performed 24 hours after the third infusion to evaluate a
possible cumulative effect of three consecutive administrations
of the drug. TxB2 and PGE2 production by PMNs from three
healthy volunteers was also analyzed. The effect of various
doses of methyiprednisolone on the urinary excretion of TxA2
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metabolites (TxB2 and its major f3 oxidation metabolite, 2,3-
dinor-TxB2), PG!2 metabolites (6-keto-PGF1, and its major f3
oxidation product, 2,3-dinor-6-keto-PGF1) and PGE2 was also
evaluated. Twenty-four-hour urine specimens were obtained
from patients of group 1, 2 and 4 before and immediately after
the first and the third injection of methylprednisolone. Twenty-
four-hour urine collections from six healthy subjects (3 males
and 3 females) were also performed. Immediately after collec-
tion, portions of the urine samples were stored at —20°C until
assayed.
In some patients (group 2) the direct in vitro effect of different
concentrations of methyiprednisolone on eicosanoid synthesis
by PMNs was also examined. PMNs were obtained before
methylprednisolone treatment and exposed for six hours to
different amounts of methylprednisolone which corresponded
to mean peak plasma concentrations measured after in vivo
administration of 1 and 15 mg/kg methylprednisolone, respec-
tively.
Pharmacokinetics
Methylprednisolone concentration was determined by high-
performance liquid chromatography (HPLC) in plasma ob-
tained after centrifugation of whole blood collected in tubes
containing heparin (10 U/ml). Plasma (1 ml) after addition of 1
g il-deoxycortisol as internal standard was diluted (1:1) with
distilled water. To each tube 8 ml dichloromethane was added,
samples were vortexed for 20 seconds and centrifuged for 15
minutes at 1,700 x g. The organic layer was separated and
evaporated to dryness. The residue was redissolved in 200 pA of
acetonitrile/water (pH 3.0 with H3P04): 26/74 (vol/vol) (mobile
phase). Fifty microliters aliquot was injected into a reverse-
phase high performance column (Pecosphere-3 x 3C C-18 33 X
4.6 mm, Perkin-Elmer, Norwalk, Connecticut, USA) connected
with a 342 liquid chromatograph (Beckman Instruments, Ful-
lerton, California, USA) equipped with a Model 160 UV detec-
tor (Beckman) operating at 254 nm. Samples were eluted in
isocratic conditions at a 1.3 mI/mm flow rate. The retention time
of methylprednisolone and internal standard were 2.3 and 3.6
minutes, respectively. Internal calibration curves of methyl-
prednisolone were prepared for each set of samples. Linearity
was found over a range of concentrations of 0.01 to 30 sg/ml.
The detection limit was 10 nglml. Pharmacokinetic parameters
for methylprednisolone were calculated by the noncompart-
mental analysis according to Gibaldi and Perrier [17] and Benet
and Galeazzi [18].
Methyiprednisolone plasma protein binding
Protein binding was measured by ultrafiltration technique
using the Centricon 10 Microconcentrator system (Amicon,
Corp., Danvers, Massachusetts, USA), placing in the sample
reservoir 2-mi portions of plasma. The samples were centri-
fuged at 3,000 x g for 15 minutes at 37°C using a Beckman
model J2-21 centrifuge (Beckman) with a fixed-angle rotor
(JA-21, angle 40°). The collected volume of ultrafiltrate ranged
between 10% and 15% of the initial sample volume. The
percentage of binding was determined as follows: percent
bound = (T — F)/T x 100, where F denotes the free drug
concentration determined in the ultrafiltrate and T is the total
drug concentration introduced into the system. The concentra-
tions were determined by HPLC technique as described above.
Cellular kinetics
The following monoclonal antibodies were used: T3 (anti-
CD3), T4 (anti-CD4), T8 (anti-CD8) and B4 (anti-CD19) all gifts
from Dr. S.F. Schlossman (Dana Farber Cancer Institute,
Boston, Massachusetts, USA); B73. 1 (anti-CD16) provided by
Dr. G. Trinchieri (Wistar Institute, Philadelphia, Pennsylvania,
USA). Isotype-matched monoclonal antibodies that do not
react with human leukocytes cells were used as controls to
exclude Fe-related binding. Immunofluorescence analysis was
performed on whole blood cell preparations. Briefly, 100 pA
samples of whole blood were incubated for 30 minutes at 4°C
with the primary antibody in 12 x 75 mm tubes. Four ml of
medium containing 2.5% human AB serum was added and the
cells were pelleted and resuspended in 100 .d of fluorescin
isothiocyanate-conjugated goat anti-mouse Ig (Tago, Burlin-
game, California, USA). The cells were further incubated for 30
minutes at 4°C and the erythrocytes were lysed with an hypo-
tonic buffer and finally fixed with 1% formalin phosphate
buffered saline (PBS). All tubes were stored in the dark at 4°C
until flow cytometric analysis.
Flow cytometry was performed on a FACScan cytometer
(Becton Dickinson, Mountain View, California, USA) using the
488 nm line of an argon ion laser as previously described [19].
Forward and right angle light scatter properties were used to
identify the lymphocyte populations.
The absolute numbers of the different lymphocyte subpop-
ulations were calculated from the percentage of lymphocyte
subsets obtained by flow cytometry and from the simulta-
neously obtained absolute lymphocyte counts, which were
determined using a Hemalog D cell counter (Technicon, Tarry-
town, New York, USA).
Isolation of human polymorphonuclear leukocytes
Heparinized (10 U/ml) venous blood was diluted with an
equal volume of 0.9% NaCl and layered on Ficoll-Paque (Phar-
macia Fine Chemicals, Upssaia, Sweden) [201. After centrifu-
gation at 400 x g for 40 minutes at 18 to 20°C, the bottom
fraction containing the erythrocytes and granulocytes was
mixed with 4 volumes of Emagel (Behringwerke AG, Marburg,
Germany) and erythrocytes were allowed to sediment at 4°C for
30 to 35 minutes. Thereafter supernatant was removed, centri-
fuged at 500 x g for seven minutes at 4°C and the pellet washed
once by centrifugation in CA and Mg free-Hanks Bal-
anced salt solution (HBSS) (Tris 27.5 mi, Na2HPO4 0.7 mM,
KH2PO4 0.74 mivi, KCI 5.4 mi, NaCI 136 m, dextrose 9.6
mM). The remaining erythrocytes were removed by ammonium
chloride lysis at 4°C and subsequent centrifugation. After
washing, the cell pellet was finally suspended at 2 x 106 cell/mI
in HBSS supplemented with CaCI2 1.87 mM and MgSO4 0.8
mM. PMNs accounted for about 95% of the total leukocyte
content of the purified preparation and cell viability measured
by trypan blue exclusion was greater than 98%.
Aliquots of PMN suspension (1 ml each) were incubated a
37°C for 30 minutes in the presence of calcium ionophore
A23l87 (final concentration 2 or 10 M) or the vehicle [0.1%
dimethylsulfoxid (DMSO), unstimulated]. At the end of the
incubation period the samples were placed in ice and immedi-
ately centrifuged at 2,200 x g at 4°C for 15 minutes. Supernatant
was stored at —20°C before radioimmunoassay (RIA).
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For in vitro studies, freshly isolated PMNs were incubated
for six hours at 37°C in Medium 199 (Gibco, Paisley, UK) in the
presence of methylprednisolone (1.3 or 40 tM) or the vehicle
(DMSO 0.04%). At the end of the incubation period, cells were
washed with cold HBSS and then adjusted to 2 x 106 cell/mI in
HBSS containing calcium and magnesium. Aliquots of PMNs (1
ml) were exposed to calcium ionophore A23 187 or its vehicle as
described above.
Urine extraction
Urine samples (20 ml), spiked with a tracer amount of
[3H]TxB2, [3H]6-keto-PGF1,, and [3HIPGE2 (220, 183 and 186
Ci/mmol, respectively; Amersham International, plc, Bucking-
hamshire, UK), were centrifuged at 2,000 x g at 4°C for seven
minutes. Supernatant was acidified with formic acid and applied
to C18 disposable column (Sep-pak, Millipore, Milford, Massa-
chusetts, USA), previously activated with methanol and water
and eluted with ethylacetate. The eluates were dried under a
nitrogen stream and redissolved in 100 tl of water (pH 3 with
H3P04)/acetonitrile 68:3 2 (vol/vol). Samples were isocratically
eluted at room temperature with a mobile phase of water (pH 3
with H3P04)/acetonitrile 68:32 (vol/vol) at a flow rate of I
mLlmin on a reverse phase column (Ultrasphere ODS, Altex
Scientific Co., Berkeley, California, USA, 25 cm x 4.6 mm)
connected with a Varian liquid Chromatograph (Model 5000,
Varian, Walnut Creek, California, USA). Retention times,
assessed by recording the detector output signal 196 nm after
HPLC injection of the corresponding authentic standards were:
6.8 minutes for 2,3-dinor-TxB2, 12.8 minutes for TxB2, seven
minutes for 6-keto-PGF1, 11 minutes for 2,3-dinor-6-keto-
PGF1, and 18 minutes for PGE2. Three fractions were col-
lected: fraction I (from 4 to 9 mm) containing 6-keto-PGF1 and
2,3-dinor-TxB2, fraction II (from 10 to 15 mm) containing TxB2
and 2,3-dinor-6-keto-PGF1 and fraction III (from 16 to 21 mm)
for PGE2. HPLC fractions were lyophulized, resuspended in 20
mM phosphate buffer (pH 7.4) and analyzed for TxB2, 2,3-dinor-
TxB2, 6-keto-PGF1 , 2,3-dinor-6-keto-PGF1 and PGE2. Au-
quots of each fraction were counted for radioactivity recovery
which ranged between 55% and 65%.
Measurement of eicosanoids
TxB2, 6-keto-PGF1, and PGE2 were measured by RIA using
specific antibodies, as previously described [211. RIA measure-
ments of 2,3-dinor-TxB2 and 2,3-dinor-6-keto-PGF1,, were de-
veloped using anti-TxB2 and anti-6-keto-PGF1,, antibodies
cross reacting with the corresponding dinor-metabolites (35%:
2,3-dinor-TxB2 and 36%: 2,3-dinor-6-keto-PGF1,, respective-
ly). Briefly, 5000 dpm of [3H]TxB2 or [3H]6-keto-PGF1 was
incubated, respectively, with anti-TxB2 (final dilution in the
assay of 1:200,000) or anti-6-keto-PGF1,, (final dilution in the
assay of 1:150,000) for 24 hours at 4°C in a final volume of 1.5
ml. The binding of [3H]TxB2 or [3H]6-keto-PGF1 was inhibited
by unlabeled 2,3-dinor-TxB2 or 2,3-dinor-6-keto-PGF1 in a
linear fashion, over the range of I to 100 pg/mi, with an 1C50
(concentration of unlabeled antigen which displaces by 50% the
binding of the tracer) of 16 and 23 pg/mi, respectively. Separa-
tion of the antibody-bound from free ligand was achieved by
rapidly adding 0.1 ml human plasma and 10 mg of charcoal
(Norit A) suspension and subsequent centrifugation at 1,700 x
g for 10 minutes at 4°C. The smallest concentration that could
be measured with 95% confidence was 2 pg/mI for both assays.
The cross reactivity at 50% displacement for the TxB2 antise-
rum was: 6-keto-PGF1 ,: <0.008%, for anti-6-keto-PGF1,,
TxB2: <0.006%. Intra- and inter-assay variability averaged 7
and 10%, respectively, over a range of 2,3-dinor-TxB2 or
2,3-dinor-6-keto-PGF1 concentrations from 1 to 100 pg/mi.
Validation of urinary RIA measurements was obtained by
dilution and recovery studies, detection of homologous immu-
noreactivity in the HPLC fractions corresponding to the reten-
tion times of the authentic standards, and comparison with gas
chromatography negative ion chemical ionization mass spec-
trometry 122]. Eicosanoid production by PMNs and urinary
excretion rate were expressed as pg/b6 cells and ng/hr, respec-
tively. Results of in vitro studies were expressed as percentage
inhibition of eicosanoid production by PMNs exposed to meth-
ylprednisolone with respect to PMNs exposed to vehicle.
Statistical analysis
Results are means SD.
Since data on leukocyte, lymphocyte subset and platelet
count, serum immunoglobulins (IgA, IgG, 1gM) as well as
eicosanoid measurements had standard deviation which in-
creased as the mean value did, they were log transformed
before statistical analysis was performed [23]. Data were sub-
sequently analyzed by between-within analysis of variance.
Multiple comparisons were performed using Tukey test and
statistical significance defined as P < 0.05. The Mann-Whitney
test was used to compare TxB2 and PGE2 release by PMNs as
well as eicosanoid urinary excretion in patients (basal levels)
and controls. Student's t-test for paired data was used to
compare data obtained from in vitro studies.
Results
Plasma methylprednisolone
The mean plasma concentration time curves for methylpred-
nisolone in patients of groups 1, 3, and 4 are shown in Figure 1.
All three disposition curves decayed in a monoexponential
fashion. Twenty-four hours after the first and third infusion,
methylprednisolone levels were undetectable (<10 nglml) in all
patients. Table 2 shows the mean pharmacokinetic parameters
of methylprednisolone. In patients of group 2 the mean phar-
macokinetic parameters of methyiprednisoione were compara-
ble to group 1 (data not shown). After normalizing the measured
steroid concentration by the administered dose, the concentra-
tion data for the two lower doses (1 and 5 mg/kg, data not
shown) were superimposable. This was consistent with a linear
disposition. Three out of the six patients receiving the highest
dose (15 mg/kg) instead showed marked non-linear kinetics,
since the mean area under the plasma concentration-time curve
(AUC) value was 86.71 4.66 pg/ml x hr, mean total body
clearance (CL) was 0.174 0.009 liter/hr/kg, and t-l/2 was 4.17
1.29 hours. In the other three patients pharmacokinetic
parameters (AUC: 40.19 4.39 tg/ml x hr, CL: 0.376 0.041
liter/hr/kg, t-1/2: 2.93 0.17 hr, C0: 11.30 1.19 p,g/mi) were in
good agreement with linear kinetics; in fact concentration data,
normalized by the dose, were superimposable with those of
patients given the lower doses. The mean plasma protein
binding of methylprednisolone was essentially constant over
102.
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Table 2. Pharmacokinetic parameters concerning the first dose of
methylprednisolone
Parameter
Dose mg/kg
1 5 15
t-1/2 hr 2.28 0.19 2.47 0.56 3.54 0.95
MRT hr 3.53 0.30 3.55 0.95 4.94 1.40
CL liter/hr/kg 0.44 0.08 0.41 0.07 0.29 0.11
V liter/kg 1.42 0.16 1.43 0.14 1.37 0.32
Vss liter/kg 1.53 0.18 1.42 0.20 1.32 0.30
AUC p.g/ml X hr 2.35 0.4.4 12.44 2.08 60.01 23.34
Co p.g/ml 0.46 0.08 3.12 1.12 14.41 4.97
Abbreviations are: t-1/2, elimination half-life; MRT, mean residence
time; CL, total body clearance; V, apparent volume of distribution;
Vss, steady state volume of distribution; AUC, area under the plasma
concentration-time curve; Co, concentration at the end of infusion.
the range of the concentrations investigated (0.17 to 31 g/m1)
and averaged 73.6 56%.
Leukocyte and lymphocyte subset kinetics
In all groups, six hours after glucocorticoid infusion there
was a marked drop of lymphocytes (P < 0.05 vs. basal values),
whose count returned to pre-treatment values at 24 hours. Data
obtained 24 hours after last steroid administration were compa-
rable to those obtained 24 hours after the first or to pre-
treatment values. As expected, in all groups CD4 cells showed
a significant (P < 0.01) decrease at six hours after the first
infusion of steroid as compared with basal values, then CD4
cells returned to basal level at 24 hours after the first steroid
infusion. The same was observed after the third methylprednis-
olone infusion in all groups. The kinetics of CD8 cells showed
a trend similar to the total lymphocytes and CD4 cells for each
group. The different doses of steroids employed in the four
groups did not result in different effects on total lymphocyte,
CD4 and CD8 cell counts at any time (Table 3). The count of
CD16 cells was numerically reduced six hours after the first
infusion in respect to basal values in groups 1, 2, and 3, then the
values tended to increase, although not significantly, 24 hours
Fig. 1. Plasma concentration-time profiles of
methylprednisolone following infusion of
1 mg/kg (——), 5 mg/kg (—0—) and 15 mg/kg
(—U-) of methyiprednisolone as its succinate
ester. Values are mean SD.
after the third steroid infusion. B cells (CDl9) count showed a
tendency to decrease at six hours after the first infusion, which
reached the statistical significance (P < 0.05) in groups 1, 2 and
3. Twenty-four hours after the first steroid infusion CDl9
count was comparable to basal value. Monocytes showed a
common trend to drop six hours after the first infusion of
methylprednisolone. The values obtained at 24 hours after the
first and the third infusion of methylprednisolone were almost
superimposable to the basal values in each group. As expected,
the counts of eosinophils were significantly (P <0.05) reduced
at each time point with respect to basal values in the four groups
of patients. Neutrophil count was not significantly affected by
the treatment in groups 1, 2, and 3. In group 4 neutrophils were
significantly increased (P < 0.05) at 24 hours after the first and
the third steroid infusion as compared with basal values.
Platelet count as well as IgG, IgA and 1gM serum concentra-
tions were not significantly changed at 6 and 24 hours after the
first and third infusion in respect to the basal levels in all groups
(data not shown).
Eicosanoid release by PMNs ex vivo
TxB2 and POE2 release by PMNs was evaluated in patients
receiving 1 mg/kg (groups 1 and 2) and 15 mg/kg (group 4)
methylprednisolone. Eicosanoid release by PMNs was assessed
in a 30-minute incubation time in the absence or in the presence
of CA ionophore, A23 187, an agent known to initiate arachi-
donic acid hydrolysis which mainly results from phospholipase
A2 activation [24, 25].
TxB2 production by unstimulated PMNs from patients of
group 1 was 19.1 3.2 pg/l06 cells before steroid administra-
tion. After the first infusion of 1 mg/kg methylprednisolone,
spontaneous TxB2 release by PMNs was not modified (6 hr,
20.1 13.1; 24 hr, 21.8 14.5 pg/b6 cells), while it tended to
decrease, although not significantly, after the third steroid
infusion (11.4 8.2 pg/106 cells). PMNs incubation with A23 187
resulted in a fivefold increase in TxB2 release before the steroid
infusion (995 49.9 pg/l06 cells). One milligram per killogram
methylprednisolone had no effect on A23187-induced TxB2
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Table 3. Kinetics of leukocyte and lymphocyte subset counts measured before and after the first and the third infusion of 1 mg/kg (group I, N
= 7; group 2, N = 5), 5 mg/kg (group 3, N = 5) and 15 mg/kg (group 4, N = 6) methylprednisolone (MP) in patients with glomerular diseases
Lymphocytes CD4 CD8 CDI6 CD19 Monocytes Eosinophils Neutrophils
Group 1
tO 2221 1341 1014 530 744 475 196 118 299 444 404 141 248 197" 3544 971
6 662 2Ol 166 33 244 lO3 132 38 122 149" 154 84 44 25 5154 1382
24 2278 786 1048 303 757 353 172 122 284 292 477 162 97 102 5815 2056
t24t 3010 914 1393 486 960 400 207 118 415 316 558 146 110 198 5281 1310
Group 2
0 1540 434 618 90 358 117 155 59 150 103 388 103 187 73" 5436 2206
t6 746 446 78 1l 150 49 116 20 44 30" 214 l40 28 15 6363 1323
24 1616 772 567 101 346 219 171 40 181 88 441 167 62 44 7058 2297
24t 2169 1104 805 74 424 291 138 52 349 196 615 294 45 27 8690 3161
Group 3
0 1948 679 802 290 563 246 344 371 251 148 890 621 304 188" 8992 6411
6 540 9l 138 24 165 39 128 87 93 41C 196 l09 90 118 5552 2719
24 1642 755 587 260 516 300 223 142 226 148 806 405 54 42 9420 4576
24f 2302 1152 845 407 626 300 507 455 159 45 1006 456 134 238 8940 2689
Group 4
0 1492 548 667 168 530 282 137 61 129 72 416 151 282 l671 4770 l926
6 703 492 162 5& 234 174 193 131 65 27 262 272" 42 21 5720 2780
24 1592 801 649 464 539 313 201 51 189 91 391 247 44 12 11842 4620
24t 2376 1817 964 602 570 362 300 345 469 583 663 182 139 275 10111 3659
Values are mean SD; cell counts are expressed as number of ce1ls/d. Abbreviations are: t 0, basal; t 6, 6 hr after the first MP infusion; t 24,
24 hr after the first MP infusion; t 24t, 24 hr after the third MP infusion.
r < o.oi
b P < 0.05 vs. t 0, t 24, t 24t
005 vs to t 24
' P < 0.05 vs. t 6, t 24, t 24t
P < 0.01 vs. t 24, t 24t
Fig. 2. Ex vivo TxB2 and PGE2 release (pg/
106 cells) by PMNs in patients receiving 1 mgI
kg methylprednisolone. Methylprednisolone
was given by a 25 minute intravenous infusion
for three consecutive days. PMNs were
isolated from venous blood collected before, 6
and 24 hours after the first infusion and *24
hours after the third infusion of
methylprednisolone. PMNs were incubated at
37*C for 30 minutes in the presence of A23l87
(10 /SM) or the vehicle (0.1% DMSO,
unstimulated). Results are mean SD (N =
7). TxB2 and PGE2 release by PMNs was not
significantly (P> 0.05) affected by 1 mg/kg
methylprednisolone.
release by PMNs (6 hr, 73.0 32.5; 24 hr, 77.9 45.2 pg/b6
cells). TxB2 synthesis was slightly reduced, although not sig-
nificantly, 24 hours after the third infusion of 1 mg/kg methyl-
prednisolone (50.6 15.0 pg/b6 cells, Fig. 2). The spontaneous
release of PGE2 by PMNs was 13.1 8.5 pg/b6 cells before
steroid treatment. PGE2 production was unchanged in PMNs
isolated after the first and the third administration of 1 mg/kg
methylprednisolone (6 hr, 13.5 7.7; 24 hr, 20.0 7.5 pg/106
cells; 24 hours after the third infusion of steroid, 10.3 5.9
pg/b6 cells). Stimulation of PMNs with A23 187 increased PGE2
production by threefold above the corresponding values for
spontaneous release (36.5 14.3 pg/b6 cells). Methylprednis-
olone did not affect the A23 187-induced PGE2 release of PMNs
either after the first (6 hr, 36.2 14.0; 24 hr, 44.6 21.8 pg/b6
cells) or the third infusion of steroid (31.4 20.0 pg/b6 cells,
Fig. 2).
As observed in patients of group 1, 1 mg/kg methyipredniso-
lone did not reduced TxB2 and PGE2 synthesis by PMNs from
patients with diffuse proliferative glomerulonephritis (group 2).
This was true either when spontaneous release or A23 187 (2 or
Fig. 3. Ex vivo TxB2 and PGE2 release (pg/
1O') by PMNs in patients receiving 15 mg/kg
methylprednisolone. Methyiprednisolone was
given by a 25 minute intravenous infusion for
three consecutive days. PMNs were isolated
from venous blood collected before, 6 and 24
hours after the first infusion and *24 hours
after the third infusion of methylprednisolone.
PMNs were incubated at 37°C for 30 minutes
in the presence of A23 187 (10 sM) or the
vehicle (0.1% DMSO, unstimulated). Results
are mean SD (N = 6). TxB2 and PGE2
release by PMNs was not significantly (P >
0.05) affected by 15 mg/kg
methylprednisolone.
10 gM) induced synthesis of TxB2 and PGE2 was measured
(Table 4).
Spontaneous TxB2 release was not affected by 15 mg/kg
methylprednisolone (basal, 15.7 9.3; 6 hr, 11.9 4.3; 24 hr,
17.7 10.6; 24 hr after the third infusion, 12.8 10.9 pg/b6
cells; Fig.3). Stimulation with A23187 resulted in an increased
TxB2 production by three- to fourfold above the spontaneous
release either before (52.0 23.8 pg/b6 cells) or after steroid
treatment (6 hr, 45.0 13.7; 24 hr, 45.3 16.0; 24 hr after the
third infusion, 37.0 18.9 pg/106 cells; Fig. 3). Furthermore,
spontaneous PGE2 production was unaffected by 15 mg/kg
methylprednisolone (basal, 10.0 2.9; 6 hr, 7.7 3.6; 24 hr,
14.3 9.6; 24 hr after the third infusion, 8.3 4.4 pg/b6 cells).
A23 187 stimulation produced a threefold increase in PGE2
production either before (31.2 12.1 pg/b6 cells) or after
methylprednisolone administration (6 hr, 24.0 8.7; 24 hr, 48.8
37.6; 24 hr after the third infusion, 23.1 17.5 pg/b6 cells;
Fig. 3). TxB2 and PGE2 synthesis by PMNs in healthy volun-
teers was higher, although not significantly, than values of
patients either as far as spontaneous release (TxB2, 19.2 16.1
pg/b6 cells; PGE2, 20.0 14.4 pg/I 06 cells) or A23 187 induced
synthesis (TxB2, 81.0 32.1 pg/b6 cells; PGE2, 78.0 55.8
pg/b6 cells); the trend was statistically significant (P < 0.01) for
spontaneous PGE2 release in group 2.
In vitro studies
In PMNs exposed in vitro for six hours to 1.3 /LM methyl-
prednisolone the production of TxB2 and PGE2 was partially
suppressed either when spontaneous release (TxB2, 40 15%;
PGE2, 50 27%) or A23187-stimulated synthesis (A23187 2
lsM; TxB2, 43 19%; PGE2, 43 24%; A23187 10 pv1; TxB2,
54 23%; PGE2, 49 12%) was measured. The inhibitory
effect of methylprednisobone was not dose-related, thus 40 sM
methylprednisolone did not further reduce eicosanoid release
by PMNs (unstimulated, TxB2: 40 17%; PGE2, 50 31%;
A23187 2 jiM, TxB2, 31 18%; PGE2, 32 22%; A23187 10
jiM; TxB2, 49 30%; PGE2, 51 17%).
Eicosanoid urinary excretion
Table 5 shows the urinary excretion of TxB2, 2,3-dinor-TxB2,
6-keto-PGF1, 2,3-dinor-6-keto-PGF1 and PGE2 in patients of
group I before and after methylprednisolone administration.
The basal urinary excretion of either TxA2 or prostaglandin
metabolites was significantly (P C 0.01) lower in all patients as
TxB2 pg/b6 cell
Unstimulated
A23 187
2 fLM
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Table 4. Ex vivo eicosanoid release by PMNs in patients with diffuse proliferative glomerulonephritis receiving 1 mg/kg of methylprednisobone
(MP)
Basal 15.3 9.0 66.3 44.9 82.3 35.0 4.5 2.7 47.5 28.9 35.5 16.9
6 hr 12.1 7.9 47.8 23.5 82.0 50.0 4.6 2.8 40.7 24.4 32.1 18.2
24 hr 12.2 7.6 81.8 46.5 60.0 51,2 16.6 11.4 68.5 34.4 42.0 23.2
24 hr° 6.1 3.5 90.5 36.1 53.8 30.1 4.1 3.3 68.3 34.1 49.0 29.6
10 jLM
PGE2 pg/b6 cell
Unstimulated
A23 187
2 JiM 10 JiM
PMNs were isolated from venous blood collected before, 6 and 24 hours after the first infusion and 24 hours after the third infusion of MP and
incubated at 37°C for 30 minutes in the presence of A23 187 (2 or 10 JiM) or the vehicle (0.1% DMSO, unstimulated). Results are mean 50 (N
= 5)
* After 3rd infusion
b P C 0.01 vs. basal, 6 hr, 24 hr*
80 80
C0
UDV0
a.
60
40
20
0
60
C
.2 400
'00
a.
wO 20
Unstimulated A231 87
T
r'iiIii 11
0 6 2424° 0 6 2424*
Time, hours
0 6 2424* 0 6 2424*
Time, hours
0
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Table 5. Eicosanoid urinary excretion (ng/hr) in patients with glomerular diseases receiving 1 mg/kg of methylprednisolone (MP) assessed in
24-hour urine specimens collected before and after the first and the third injection of MP
2,3-dinor- 6-keto- 2,3-dinor-6-
TxB2 TxB2 PGF1, keto-PGF1 PGE2
Group 1
Basal 0.45 0.l7a 2.40 + 0.45" 1.33 0.46a 1.10 0.29k' 0.48 0.29"
1st MP injection 0.56 0.47 2.35 0.79 1.48 0.74 1.03 0.65 0.65 0.63
3rd MP injection 0.79 ÷ 0.70 2.10 0.74 1.57 1.00 1.34 0.57 0.68 ÷ 0.18
Group 2
Basal 0.58 0.25" 3.34 1.22" 1.24 0.69a 1.41 0.76" 2.23 2.19
1st MP injection 1.03 0.76 3.56 1.45 1.53 0.78 2.45 1.75 2.18 1.27
3rd MP injection 1.17 0.98 4.27 2.56 2.00 0.99 2.28 1.06 2.18±1.45
Urinary excretion of eicosanoids in healthy volunteers (mean SD, N = 6)was: TxB2, 1.45 + 0.72; 2,3-dinor-TxB2, 14.13 2.89; 6-keto-PGF1,
11.16 1.80; 2,3-dinor-6-keto-PGF1, 9.37 2.27; PGE2, 3.00 1.54 (ng/hr). Urinary excretion of eicosanoid metabolites was not affected by I
mg/kg MP (P> 0.05).
"P < 0.01 vs. healthy volunteers
,, 1%.)
0)
0.
0
6)
10
ii
0
compared to healthy subjects. One milligram per kilogram
methyiprednisolone treatment was not associated with any
significant change in urinary excretion of either TxA2 or pros-
taglandin metabolites (Table 5). In patients of group 2 the basal
urinary excretion of TxA2 and PGI2 metabolites was signifi-
cantly (P < 0.01) lower as compared to healthy subjects (Table
5). In contrast the urinary excretion of PGE2 was comparable to
controls (Table 5). In these patients, as observed in group 1,
urinary eicosanoid excretion was not modified by 1 mg/kg
methyiprednisolone administration (Table 5).
In five out of six patients of group 3 the basal excretion of
urinary TxB2, 2,3-dinor-TxB2, 6-keto-PGF1 and 2,3-dinor-6-
keto-PGF1, was markedly reduced as compared to healthy
subjects (TxB2, 0.40 0.21 vs. 1.45 0.72 ng/hr, P < 0.01;
2,3-dinor-TxB2, 3.10 2.02 vs. 14.13 2.89 ng/hr, P < 0.01;
6-keto-PGF1,, 2.12 1.19 vs. 11.16 1.80 ng/hr, P < 0.01;
2,3-dinor-6-keto-PGF1, 0.87 0.49 vs. 9.37 2.27 ng/hr, P <
0.01). On the contrary, the urinary excretion of PGE2 was
comparable to controls (2.42 1.62 vs. 3.00 1.54 ng/hr).
As shown in Figure 4, 15 mg/kg methylprednisolone treat-
ment did not alter urinary excretion of either TxA2 or PGI2
metabolites. On the other hand PGE2 urinary excretion was
significantly reduced (P < 0.01) by steroid administration
(basal, 2.42 1.62; first methylprednisolone infusion, 0.60
0.34; third methylprednisolone infusion, 0.79 0.50 ng/hr).
The sixth patient (#2 1), with systemic lupus erythematosus,
had basal urinary levels of TxB2 and 2,3-dinor-TxB2 in excess
of 5 SD of the normal mean; in contrast, basal urinary levels of
PGI2 metabolites and PGE2 were lower than mean values of
controls. In this patient 15 mg/kg methyiprednisolone adminis-
tration resulted in a marked decrease either of TxA2 urinary
metabolites or urinary PGE2.
Discussion
Results of pharmacokinetic parameters showed that all pa-
tients given 1 and 5 mg/kg methylprednisolone, as well as three
out of the six patients given 15 mg/kg, had a linear type kinetic
disposition of the drug. In the remaining three patients on 15
mg/kg, the pharmacokinetics were of a non-linear type. Areas
under plasma concentration-time curves did not correlate with
the dose of methylprednisolone administered, while plasma
protein binding was comparable within the three doses. Thus
different doses of methylprednisolone resulted in major differ-
ences in patients' exposure to the drug, and within the same
dose there was a great individual variability. Of great interest,
the drop in total peripheral blood lymphocytes was not influ-
enced by the dose, within the range of doses used in this study.
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Fig. 4. Urinary excretion of eicosanoids (nglhr) in patients given 15
mg/kg methyiprednisolone. TxB2, 2,3-dinor-TxB2, 6-keto-PGF1, 2,3-
dinor-6-keto-PGF, and PGE2 were measured in 24-hr urine specimens
obtained before and immediately after the first and the third injection qf
met hylprednisolone. Data are mean SD (N = 5). "P < 0.01 vs. basal.
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Actually, we have found a dramatic drop in the absolute
number of lymphocytes six hours after the first injection of
methyiprednisolone in all patients, independently from the dose
used, while 24 hours later blood lymphocyte counts returned to
the pre-injection values. This would suggest that within the
range of doses considered, the plasma level of glucocorticoids
always exceeded the threshold required to reach the maximum
effect of total blood lymphocyte drop.
Analysis of lymphocyte subsets showed a selective decrease
in the number of circulating CD4, CD8 and CDl9 cells six
hours after methylprednisolone injection which returned to
normal at 24 hours. CDl6 was also numerically decreased at
six hours, but the difference with the basal values was not
statistically significant. Again, no statistically different effects
have been found on peripheral lymphocyte subsets among the
three different doses. These studies are in good agreement with
those of Fauci and Dale [161, who found a comparable decrease
in absolute number of circulating lymphocytes four to six hours
after therapy in normal subjects given 100 or 400 mg hydrocorti-
sone.
Circulating monocytes and eosinophils decreased numeri-
cally with all the three doses. Neutrophil count had a tendency
to increase six hours after the first intravenous infusion of
methylprednisolone. At 24 hours the increase in peripheral
neutrophil count was statistically significant for patients given
15 mg/kg.
The mechanism underlying the effect of methyiprednisolone
on lymphocyte and monocyte counts has not been fully under-
stood despite several studies. A possibility is that glucocorti-
coids are cytotoxic to lymphocytes [261 or, more likely, that the
drop in lymphocyte count is secondary to redistribution at
extravascular site [271. Another possibility [281 is that glucocor-
ticoids induce peripheral blood lymphocytes to enter the bone
marrow, as documented in experimental animals and humans.
According to some protocols, patients with proliferative
glomerulonephritis are given intravenous methylprednisolone
at doses as high as 15 mg/kg for three or more days [29, 30]. This
in term of plasma concentration of glucocorticoids is 20 to 50
times more than required to have the maximal effect on periph-
eral lymphocytes, as documented by previous study in normal
volunteers [131 and by the present study in patients. Actually
we have been unable to document that 15 mg/kg were more
effective than 1 mg/kg in inducing CD4, CD8 and CDl9
depletion from the circulation.
However, the possibility that other properties of glucocorti-
coids were dose-related cannot be ruled out on the basis of the
lack of differential effect on peripheral lymphocyte numbers.
Glucocorticoids have major anti-inflammatory properties re-
lated to their inhibitory effect on the formation of prostaglan-
dins in different cells. Particularly, methylprednisolone and
prednisolone have been shown to inhibit eicosanoid synthesis
by leukocytes in vitro [31, 32]. This occurs through the synthe-
sis of a family proteins—lipocortins—that interfere with the
early step of arachidonate metabolism by inhibiting phospholi-
pase A2 [11, 331 and, as recently documented, by a direct
inhibition of the enzyme cyclooxygenase [34, 35].
To address this, we examined the effect of methylpredniso-
lone on systemic and renal eicosanoid synthesis. The results
showed that in patients with glomerular diseases 1 and 15 mg/kg
were equally unable to reduce ex vivo TxB2 and POE2 release
by circulating PMNs. These data are in good agreement with a
recent study in healthy subjects showing that a one week
treatment with 1 mg/kg prednisone did not inhibit eicosanoid
release in whole blood [36]. At variance to what observed in ex
vivo studies, methylprednisolone partially inhibited eicosanoid
synthesis by PMNs in vitro. The lack of methyiprednisolone
effect ex vivo might be due to the fact that fresh populations of
neutrophils moving into the circulation after methyipredniso-
lone injection could produce greater amounts of eicosanoids
and offset the inhibitory effect of the steroid.
Consistent with the data on polymorphonuclear cells, urinary
excretion of TxB2 and 6-keto-PGF1 were unaltered by the
different doses of methylprednisolone. By contrast urinary
PGE2 was markedly and significantly reduced in patients given
15 but not 1 mg/kg. Urinary POE2 is a marker of the renal
synthesis of the molecule as documented by studies with
radioactive arachidonate infused into the renal artery [37] and
by stop-flow experiments which localized PGE2 entry into the
loop of Henle [381. Recent studies have documented that in
patients with renal disease, glomerular filtration is dependent on
intact renal cyclooxygenase [39, 40], inasmuch as cyclooxygen-
ase inhibitors reduce glomerular filtration rate by reducing renal
PGE2 synthesis [41, 42]. Thus the observed inhibitory effect of
15 mg/kg methylprednisolone on renal PGE2 in our patients
might not be desirable.
Finally glucocorticoids have an inhibitory effect on interleu-
kin-2 and interleukin-2 receptor gene expression as recently
documented [43], the effect on interleukin-2 gene being greater
than that on interleukin-2 receptor gene [43]. In vitro dexam-
ethasone inhibits the interleukin-2 gene by inhibiting its tran-
scription and by decreasing the stability of interleukin-2
mRNA. Both effects were dose dependent and were achieved in
vitro at a concentration of 1 M [43]. It would be useful to know
whether different doses of glucocorticoids given in vivo may
have a different effect on T lymphocyte interleukin-2 mRNA.
These types of studies might not be feasible in vivo due to the
difficulties in obtaining enough T lymphocytes from the circu-
lation after administering glucocorticoids. Extrapolating from
our pharmacokinetic data it can be observed, at least in patients
with glomerular diseases, that concentrations of the order of 1
M are already achieved after 1 mg/kg steroid administration,
again making it difficult to predict that 15 mg/kg will be any
better than 1 mg/kg in term of inhibiting interleukin-2 mRNA.
We conclude that 1 mg/kg methylprednisolone given to
patients with glomerular diseases has the same effect on periph-
eral total blood leukocyte and lymphocyte subset counts than 5
or 15 mg/kg. The same is true for eicosanoid synthesis by
peripheral polimorphonuclear cells. Urinary excretion of PGE2
is inhibited by 15 mg/kg but not by 1 mg/kg, but theoretically
this may not help patients with renal dysfunction.
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